Race Oncology's Breakthrough in Cancer Cell Treatment
Race Oncology's Breakthrough in Cancer Cell Treatment
Key Takeaways (TLDR)
Combining bisantrene with decitabine greatly enhances the destruction of cancer cells, potentially expanding decitabine's use to solid tumors.
The study involved screening the combination across 143 cancer cell lines from over 20 human tissues, encompassing both solid and blood cancers.
This development suggests substantial interest for owners of marketed formulations of decitabine, including oral variants, potentially leading to new treatment avenues for various types of cancer.
Promising preclinical findings show that a combination of bisantrene and decitabine greatly enhances the destruction of cancer cells across a wide variety of types.
Why it Matters
The promising preclinical findings of combining bisantrene with decitabine to enhance the destruction of cancer cells across various types could lead to new treatment avenues and potentially benefit individuals with solid tumors such as lung, prostate, pancreas, breast, and head and neck cancers. This breakthrough may have a significant impact on the future of cancer treatment and highlights the potential for a shift in the use of decitabine from blood cancers to solid tumors.
Summary
Race Oncology Ltd CEO Dr Daniel Tillett discusses promising preclinical findings indicating that combining bisantrene with decitabine enhances the destruction of cancer cells across a wide variety of types, potentially expanding decitabine's use beyond blood cancers to solid tumours. The study involved screening the combination across 143 cancer cell lines from over 20 human tissues, showing a significant increase in cancer cell death with 92% of the cell lines exhibiting improved outcomes. This development suggests substantial interest for owners of marketed formulations of decitabine, including oral variants.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Race Oncology's Breakthrough in Cancer Cell Treatment.